Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-05-16Clinical Trial Update: Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy [Phase 3]
Phase 3 trial comparing single-agent ofatumumab with single-agent rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab…
-
CLINICAL_TRIALS trial_result · 2018-05-14Clinical Trial Update: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT [Phase 2]
Phase 2 study in poor-risk diffuse large B-cell lymphoma using total lymphoid irradiation and anti-thymocyte globulin, followed by matched a…
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF [Phase 1]
Phase 1 study evaluating mobilization of autologous peripheral blood stem cells using interleukin-2 and GM-CSF; the trial has completed.
-
CLINICAL_TRIALS research · 2018-04-25Clinical Trial Update: Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy [Phase 2]
A Phase II clinical trial update evaluating high-dose therapy in elderly patients with relapsed aggressive non-Hodgkin lymphoma or resistanc…
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor [NA]
Clinical trial update on biparental HLA haplotype disparate T-cell depleted transplants for patients without an HLA-compatible donor has bee…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-04-09Clinical Trial Update: Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) [Phase 1, Phase 2]
Phase 1/2 safety study of CAT-8015 in advanced B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia has completed enrollment with re…
-
CLINICAL_TRIALS withdrawal · 2018-04-05Clinical Trial Update: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 study of atezolizumab in combination with an immunotherapy agent (with or without anti-CD20 therapy) for relapsed or refractory no…
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma [Phase 2]
A multicenter Phase 2 trial sponsored by PharmaMar for relapsed/refractory aggressive non-Hodgkin lymphoma has completed enrollment and post…
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant [Phase 1]
A Phase 1 trial from Massachusetts General Hospital evaluating recipient leukocyte infusions to prevent donor graft rejection after nonmyelo…
-
CLINICAL_TRIALS research · 2018-03-20Clinical Trial Update: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma [Phase 1, Phase 2]
Dual CD19/CD22 CAR-T cell therapy is being studied in Phase 1/2 trials for relapsed and refractory Non-Hodgkin lymphoma; the current trial s…
-
CLINICAL_TRIALS research · 2018-03-19Clinical Trial Update: Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016
This clinical trial update reports a unicentric retrospective analysis of 602 young adult and adolescent patients (ages 15-30) with hematolo…
-
FDA approval · 2018-03-15FDA Approved: METHOTREXATE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Methotrexate submitted by Hospira, Inc.
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 trial results evaluate MEDI-551 (inebilizumab) in combination with immunomodulating therapies for relapsed or refractory aggressiv…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
Phase 1/2 study evaluating inotuzumab ozogamicin (CMC-544) in combination with rituximab in patients with B-cell non-Hodgkin lymphoma; resul…
-
CLINICAL_TRIALS research · 2018-03-07Clinical Trial Update: Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
This clinical trial update discusses an ongoing Phase 1/2 study of TQB2303 for aggressive CD20-positive Non-Hodgkin lymphoma, with the curre…
-
CLINICAL_TRIALS trial_result · 2018-02-14Clinical Trial Update: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial in Non-Hodgkin lymphoma evaluating autologous followed by non-myeloablative allogeneic transplantation; study termina…
-
CLINICAL_TRIALS trial_result · 2018-01-08Clinical Trial Update: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas [Phase 2]
Open-label Phase II trial evaluating intravenous BAY80-6946, a PI3K inhibitor, in relapsed or refractory non-Hodgkin lymphoma; the study is …
-
CLINICAL_TRIALS trial_result · 2017-12-29Clinical Trial Update: High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma [Phase 2]
Phase 2 trial evaluating high-dose chemotherapy with stem cell transplant for Non-Hodgkin's Lymphoma and CNS Lymphoma has completed with res…
-
CLINICAL_TRIALS trial_result · 2017-12-14Clinical Trial Update: Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
A Phase 2 trial evaluating chidamide in combination with R-GDP for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2017-12-13Clinical Trial Update: PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients [Phase 2]
Phase 2 clinical trial update evaluating PD and safety of TG-0054 in combination with G-CSF for patients with multiple myeloma and lymphomas…
-
CLINICAL_TRIALS trial_result · 2017-12-07Clinical Trial Update: Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating autologous stem cell transplant followed by donor stem cell transplant in relapsed or refractory lymphom…
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase II study evaluating the efficacy and safety of clofarabine in patients with aggressive non-Hodgkin lymphoma. The trial status is compl…
-
CLINICAL_TRIALS research · 2017-12-06Clinical Trial Update: Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) [Phase 1, Phase 2]
Phase 1/2 study investigating Antiminor Histocompatibility Complex (MiHA) T cells in patients with relapsed hematologic malignancies after m…
-
CLINICAL_TRIALS trial_result · 2017-12-02Clinical Trial Update: Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating the safety and potential antitumor effects of atorvastatin in Non-Hodgkin lymphoma; study completed with results po…
-
FDA approval · 2017-12-01FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Mozobil (plerixafor) filed by Sanofi-Aventis U.S. LLC.